Research Papers:

LL202 protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting MAPK/AP-1 signaling

Yuan Gao, Yujie Huang, Yue Zhao, Yang Hu, Zhiyu Li, Qinglong Guo, Kai Zhao and Na Lu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:63981-63994. https://doi.org/10.18632/oncotarget.11742

Metrics: PDF 2646 views  |   HTML 3731 views  |   ?  


Yuan Gao1,*, Yujie Huang1,*, Yue Zhao1, Yang Hu1, Zhiyu Li2, Qinglong Guo1, Kai Zhao1, Na Lu1

1State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China

2School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

*These authors have contributed equally to this work

Correspondence to:

Na Lu, email: [email protected]

Kai Zhao, email: [email protected]

Keywords: LL202, colitis, inflammation, AP-1

Received: June 09, 2016     Accepted: August 26, 2016     Published: August 31, 2016


LL202, a newly-synthesized flavonoid derivative, has been reported to inhibit inflammatory-induced angiogenesis. However, the exact role of LL202 in inflammation along with its mechanism has not been explored. In this study, we investigated the anti-inflammatory effect of LL202 on intestinal inflammation by establishing dextran sulfate sodium (DSS)-induced experimental colitis. LL202 attenuated DSS-induced body weight loss, colon length shortening and colonic pathological damage. The inflammatory cells infiltration, myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) activities were decreased by LL202 in a dose-dependent manner. LL202 reduced the production of pro-inflammatory cytokines in serum and colon of DSS-induced mice as well. Mechanically, LL202 could decrease the expression and nuclear translation of AP-1 to protect against DSS-induced colitis. In lipopolysaccharide (LPS)-induced THP-1 cells, LL202 markedly decreased the secretion, mRNA level and protein expression of IL-1β, IL-6 and TNF-α via inhibiting ERK/JNK/p38 MAPK pathways and the nuclear translocation of AP-1. Furthermore, these findings were confirmed in LPS-induced bone marrow derived macrophages (BMDM). In conclusion, our study demonstrated that LL202 could exert its anti-inflammatory effect via inhibiting MAPK/AP-1 signaling, which suggested that LL202 might be a potential effective drug for the treatment of inflammatory bowel diseases.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11742